Source document: https://docs-lawep.s3.us-east-2.amazonaws.com/1697799898752.pdf (Liberia)
ARTICLE https://doi.org/10.1038/s41467-022-28330-8 OPEN Population-level deﬁcit of homozygosity unveils CPSF3 as an intellectual disability syndrome gene 1,2, Asmundur Oddsson 1, Brynjar O. Jensson1, Svanborg Gisladottir 4, Asgeir O. Arnthorsson1, Hildigunnur Katrinardottir1, Run Fridriksdottir1, 1, Adalbjorg Jonasdottir1, Aslaug Jonasdottir1, Rebekah Barrick4, Jona Saemundsdottir1, 1, Gudjon R. Oskarsson1, Jurate Asmundsson5, Thora Steffensen5, Kjartan R. Gudmundsson1, 1,2, Hilma Holm 1, Jon G. Jonasson2,5, Gudny A. Arnadottir Mariella T. Simon Erna V. Ivarsdottir Louise le Roux Petur Ludvigsson6, Jon J. Jonsson2,3, Gisli Masson1, Ingileif Jonsdottir Olafur Th.
Magnusson1, Olafur Thorarensen6, Jose Abdenur4, Gudmundur L. Norddahl1, Daniel F. Gudbjartsson 1,2✉ Kari Stefansson 1,7, Hans T. Bjornsson2,3,8, Unnur Thorsteinsdottir1,2, Patrick Sulem 1✉ 3, & ; , : ) ( 0 9 8 7 6 5 4 3 2 1 Predicting the pathogenicity of biallelic missense variants can be challenging.

Here, we use a deﬁcit of observed homozygous carriers of missense variants, versus an expected number in a set of 153,054 chip-genotyped Icelanders, to identify potentially pathogenic genotypes.
We follow three missense variants with a complete deﬁcit of homozygosity and ﬁnd that their pathogenic effect in homozygous state ranges from severe childhood disease to early embryonic lethality.

One of these variants is in CPSF3, a gene not previously linked to disease.

From a set of clinically sequenced Icelanders, and by sequencing archival samples targeted through the Icelandic genealogy, we ﬁnd four homozygous carriers.
Additionally, we ﬁnd two homozygous carriers of Mexican descent of another missense variant in CPSF3.

All six homozygous carriers of missense variants in CPSF3 show severe intellectual disability, sei- zures, microcephaly, and abnormal muscle tone.

Here, we show how the absence of certain homozygous genotypes from a large population set can elucidate causes of previously unexplained recessive diseases and early miscarriage.

1 deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.


2 Faculty of Medicine, University of Iceland, Reykjavik, Iceland.

3 Department of Genetics and Molecular Medicine, The National University Hospital of Iceland, Reykjavik, Iceland.

4 Division of Metabolic Disorders, Children’s Hospital of Orange County, Orange, CA, USA.

5 Department of Pathology, The National University Hospital of Iceland, Reykjavik, Iceland.
6 Children’s Hospital Iceland, The National University Hospital of Iceland, Reykjavik, Iceland.

7 School of Engineering and Natural Sciences, University of Iceland, Reykjavik, Iceland.

8 Department of Genetic Medicine, Johns Hopkins University, Baltimore, MD, USA.
email: patrick.sulem@decode.is; kari.stefansson@decode.is ✉ NATURE COMMUNICATIONS | (2022) 13:705 | https://doi.org/10.1038/s41467-022-28330-8 | www.nature.com/naturecommunications 1 ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-022-28330-8 Genetically isolated populations that go through episodes of rapid growth are of interest to the study of the role of rare the disease.
In such variants in the pathogenesis of populations, certain deleterious sequence variants can reach higher frequencies than in large outbred populations1.

Whole- genome sequencing (WGS) of a large fraction of the Icelandic population has provided valuable insights into the genetic makeup of an isolated population, facilitating the detection of rare pathogenic genotypes2,3.
This has motivated the ﬁrst clinical sequencing effort in Iceland, mainly centered on rare disease cases referred by medical specialists at the National University Hospital of Iceland2–6.

By now, we have performed clinical WGS for 764 patients and their family members.

The current overall rate of detection of causative genotypes is 35%, comparable to other centers using next-generation sequencing7, but around 460 patients remain without a clear genetic cause.
Due to the isolation of the Icelandic population and the founder effect, some sequence variants that may be pathogenic in the homozygous states, reach elevated frequencies2.

This holds the potential of uncovering previously unidentiﬁed causes of autosomal recessive (AR) diseases8.

We have previously mapped out a large set of carriers of biallelic predicted loss-of-function (pLoF) variants in the Icelan- dic population, i.e., stop-gained, frameshift, or essential splice variants9.
In doing so, we observed an overall deﬁcit of double transmissions of pLoF variants from a pair of heterozygous par- ents to their offspring9.

Such a deﬁcit will appear if the homo- zygous genotype is expected to (A) be incompatible with early embryonic development (early miscarriage) (B) be incompatible with late embryonic development (late miscarriage, stillbirth), or (C) interfere with reproduction (e.g., by early death or severe disease).
We recently characterized one of the genotypes from this set, a homozygous loss-of-function variant in CYBC1, as the cause of a previously unknown form of chronic granulomatous disease6.

Most pLoF variants disrupt the protein and its function, and thus their pathophysiological roles are clear.

For missense var- iants, however, only a subset disrupts the function of a protein in a way that leads to disease.
Multiple methods have been devel- oped to predict the pathogenicity of missense variants, taking into account evolutionary conservation of the sequence, physio- chemical differences between amino acids, and expected effects on a protein’s structure and biological function10.
Moreover, population-genetic metrics based on the deﬁcit of observed versus expected number of sequence variants, i.e., genic con- straint scores, have shown great promise for highlighting genes where heterozygous missense variants are expected to be pathogenic11–13.

However, predicting the pathogenicity of bial- lelic missense variants remains challenging14.
Here we demonstrate that with a large dataset representative of an isolated population, it is possible to assess the pathogenicity of homozygous missense variants based on the deﬁcit of homo- zygous carriers of such variants.

Results The deﬁcit of homozygous carriers outlines potentially pathogenic genotypes.
We searched for missense variants with a deﬁcit of observed homozygous carriers, versus the expected number, in a population set of 153,054 Icelanders who were chip- genotyped and with rare variants imputed based on the WGS of 56,969 Icelanders.

The population set mainly consists of adult volunteers, at a mean age of 58.5 years.
We deﬁned a complete deﬁcit as missense variants present in the population set at a minor allele frequency (MAF) high enough to expect at least three homozygous carriers (MAF > 0.40%), assuming Hardy-Weinberg equilibrium, with no homozygous carriers observed.

We found 114 missense variants meeting these criteria, 34 of which were in known AR Mendelian disease genes (Supplementary Data 1 and Supplementary Table 1).
We observed that ﬁve of these variants presented in homozygous state in the clinical set (Table 1), a set consisting of 764 individuals previously WGS in a clinical con- text.
Among these variants were c.1016 T > C (p.Leu339Pro) (RefSeq NM_001363118.2) in SLC52A2 (MAF = 0.60%), that has caused AR Brown-Vialetto van Laere syndrome type 2 in at least four genotypically conﬁrmed homozygous carriers in Iceland2, c.655 G > A (p.Gly219Arg) (RefSeq NM_177550.4) in SLC13A5 (MAF = 0.49%), that has caused epileptic encephalopathy in at three homozygous carriers in Iceland, and c.557 A > C least (p.Glu186Ala) (RefSeq NM_000404.3) in GLB1 (MAF = 0.52%), that has caused GM1-gangliosidosis in at least one homozygous carrier in Iceland.
Homozygous missense variants in CPSF3 cause a severe intel- lectual disability syndrome.

The fourth variant, c.1403 G > A (p.Gly468Glu) (RefSeq NM_016207.3) in CPSF3, was found in homozygous state in two previously unresolved clinical cases (MAF = 0.41% in the population set; three expected homozygous carriers and none observed, Table 1).

To our knowledge, sequence variants in CPSF3 had not yet been reported to cause a disease phenotype.
The two homozygous carriers, whom we will refer to as patient A and patient B, were not closely related (meiotic distance = 12) but displayed strikingly similar phenotypes, see Table 2.

Both patients were males, born at term to non- consanguineous parents.

Both patients had an intellectual dis- ability, with seizures from infancy, failure to thrive, microcephaly, nystagmus, and a severe delay in psychomotor development.
Patient A died from pneumonia at 2 years of age, patient B is currently being treated for severe seizures (13 years old at last clinical evaluation).

Analysis of the WGS data from both patients did not reveal any other plausible genetic causes (see Methods).

Based on the frequency of the p.Gly468Glu variant in the Icelandic population, we postulated that there could have been previous, unrecognized, homozygous carriers.
The genealogical database constructed by deCODE genetics has near-complete genealogical information of Icelanders from the last century2.

This allowed us to ﬁnd three additional couples who were heterozygous carriers of p.Gly468Glu in the population set of 153,054 genotyped Icelanders, linked in the genealogical database by their offspring.

For these couples, each offspring had a 25% probability of being a homozygous carrier of p.Gly468Glu.
Combined, the three couples had ten offspring, four of whom died before eight years of age and had phenotypic features consistent with patients A and B, including intellectual disability (4/4), hypotonia/low muscle tone (4/4), seizures (3/4), and microcephaly (2/4) (Table 2).

We were able to acquire parafﬁn- embedded archival samples from two of these children, patients C and D, siblings who had died at seven and four years of age (patient C 1960–1967; patient D 1964–1968).
Whole-genome and Sanger sequencing of these samples conﬁrmed a homozygous status of p.Gly468Glu in CPSF3 in both siblings.

The siblings, whose parents were ﬁrst cousins, were part of the same extended family as patient A (meiotic distance = 5, Supplementary Fig.

1).

Importantly, analysis of WGS data from the siblings (see Methods), failed to identify any other pathogenic or likely pathogenic genotypes.
Samples from the other two suspected homozygous Icelanders, patient E (1990–1995) and patient F (1955–1956), were not available (Table 2, Supplementary Fig.

2).

However, including the phenotypes of patients E and F, intellectual disability, motor delay, and microcephaly, strongly suggests they have the same condition as the genotypically conﬁrmed CPSF3 p.Gly468Glu homozygous patients.
2 NATURE COMMUNICATIONS | (2022) 13:705 | https://doi.org/10.1038/s41467-022-28330-8 | www.nature.com/naturecommunications NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-022-28330-8 ARTICLE n i t n e s e r p t a h t , s r e d n a l e c I 4 5 0 3 5 1 , , .
/ , , e m o r d n y s e r e a L l n a V - o t t e a V - n w o r B i s i s o d i s o i l g n a g - 1 M G y h t a p o y m - E N G A N 6 / 0 4 / 0 4 / 0 3 / 0 6 / 0 % 3 − 0 1 × 2 % 3 0 0 .
% 1 0 0 .

% 3 0 0 .

A N d n a l e c I F A M % 0 6 0 .

% 9 4 0 .

% 2 5 0 .

% 1 4 0 .

% 0 6 0 .

e g n a h c n i e t o r P e g n a h c A N D c ) 8 3 g h ( n o i t i s o P a e n e G o r P 9 3 3 u e L p .

g r A 9 1 2 y G p l .

l a A 6 8 1 u G p l .

l u G 8 6 4 y G p l .

r y T 8 7 3 p s A p .

C > T 6 1 0 1 .

c A > G 5 5 6 c .

C > A 7 5 5 c .

A > G 3 0 4 1 .

c T > G 2 3 1 1 .


c 4 0 6 0 6 3 4 4 1 : 8 r h c 1 3 0 3 0 7 6 7 1 r h c : 5 6 2 8 5 0 3 3 3 r h c : 7 9 3 7 2 2 6 3 9 r h c : 0 2 9 2 5 4 9 2 r h c : 2 A 2 5 C L S 5 A 3 1 C L S 3 F S P C 1 B L G E N G Subsequently, through GeneMatcher15, we found another homozygous missense variant in CPSF3; c.1061 T > C (p.Ile354Thr) (Supplementary Table 2).
The variant was discovered through the whole-exome sequencing (WES) of two patients, whom we will refer to as G and H, from the Children’s Hospital of Orange County (CHOC).

Patients G and H were ﬁrst-degree cousins from a large consanguineous family of Mexican descent (Supplementary Table 3, Supplementary Fig.

3).

Similar to what we observed in our Icelandic patient set, the cousins presented with intellectual disability, seizures, abnormalities of muscle tone, and microcephaly (Table 2).
Furthermore, the analysis of their WES data did not yield any other pathogenic or likely pathogenic genotypes relating to their condition.

We do not observe any consistent phenotypic associations among 680 heterozygous carriers of CPSF3 p.Gly468Glu in the Icelandic population set, nor do we observe a reduction in mRNA expression in white blood cells from 150 RNA sequenced heterozygous carriers (p-value = 0.91; Effect = 0.01 SD, Supple- mentary Fig.

4).
4).

Western blot analysis of EBV transformed lymphocytes from Patient B conﬁrmed that the CPSF3 protein is expressed in a homozygous carrier (Supplementary Fig.

5).

This indicates that p.Gly468Glu does not quantitatively affect the production of the CPSF3 protein, but would rather be expected to alter the function of the protein.
The CPSF3 gene is not constrained for pLoF variants (pLI=0.00) and not notably constrained for missense variants (z-score = 3.61), which is in line with what is expected for genes in which variants cause disease under an autosomal recessive mode of inheritance16.

There is no homozygous carrier of a pLoF variant in CPSF3 among 56,969 WGS Icelanders, nor among 141,456 WES or WGS individuals on gnomAD13, although no pLoF variant reaches a high frequency in these datasets (MAFs below 0.02%).
In total, we have identiﬁed six patients who are homozygous for missense variants in CPSF3, as well as two suspected homozygous carriers, all of whom present with features of seizures, microcephaly, and abnormal intellectual disability, muscle tone.

carriers in the population set, was A homozygous missense variant in GNE causes a novel GNE allelic disorder.
The ﬁfth missense variant presenting in homo- zygous state in the clinical set, with a complete deﬁcit of homo- zygous c.1132 G > T (p.Asp378Tyr) (RefSeq NM_005476.5) in GNE (MAF = 0.59%; six expected homozygous carriers and none observed, Table 1).

The homozygous carrier was a female infant who had died shortly after birth, but had presented with acidosis, a ventricular septal defect, micro-Ebstein anomaly, and polysplenia.
The presence of a myopathic disorder was suspected, and a biological sample was acquired postmortem.

Prior to acquiring this biological sample, we performed WGS for her non-consanguineous parents (meiotic distance = 16), searching for potential recessive genetic causes for her condition.

We observed that the parents were both hetero- zygous carriers of the GNE p.Asp378Tyr variant, which is a known pathogenic variant in GNE-myopathy17,18.
GNE-myo- pathy, or Nonaka myopathy, is a progressive AR disease of muscle weakness with a typical age of onset between 20 and 40 years (ClinVar Variation ID 283278)17,18.

Although initially we did not consider this genotype to align with the severe pre- sentation of the female infant, WGS of the postmortem biological sample from her conﬁrmed that she was indeed homozygous for GNE p.Asp378Tyr.

Moreover, currently experiencing another pregnancy, and a 12-week ultrasound had shown increased nuchal thickness.
WGS of a fetal sample from this pregnancy also showed homozygosity for p.Asp378Tyr.

Importantly, WGS analysis of samples from both the deceased the parents were .

l e b a c i l p p a t o n A N , e v i s s e c e r l a m o s o t u a R A , s u o g y z o m o h Z M H , d e t c e p x e / d e v r e s b o E / O , y c n e u q e r f e e l l l a i r o n m F A M .

 - n o n S G W / S E W 3 0 6 4 6 , n o d e s a B b .
NATURE COMMUNICATIONS | (2022) 13:705 | https://doi.org/10.1038/s41467-022-28330-8 | www.nature.com/naturecommunications 3 ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-022-28330-8 c i t i r h p e n c i n o r h C ; e m o r d n y s i ; ; e v i r h t o t e r u l i a F n i e v r u c r e d n U ; ; t h g e h i ; ) e d i s t h g i r ( o t t h g u o h T d n i l b e b e l c i t s e t i ; ; d n i l b e b l c i t s a p o p y H ; s e i t l u c ﬁ f i d ) y s p o t u a ( s e i r a v o i g n d e e F ; s e i t l u c ﬁ f i d d n i l b e b i g n d e e F ; ; ; ) y s p o t u a ( o t t h g u o h T ; ) y s p o t u a ( ; ; ; / l a c i g o l o n u m m I l a t e l e k s o u c s u M l ; e v i r h t o t e r u l i a F l a r e t a l i b , e l c i t s e t d e d n e c s e d n U ; ; , t r o h S ; l y a e d l a t n e m p o e v e D l ; y t i l i b a s i d s u m g a t s y N ; s e r u z i e S ; ) 2 ( i a n o m u e n P s r a e y 2 Z M H l u G 8 6 4 y G p l .
) e g a ( .
; n o i t a p i t s n o C ; s n o i t c e f n i D R E G ; y d o b l e o h w n i f l a c e s r a p S ; ; l y a e d l a t n e m p o e v e D l , y s l a p l a r b e r e C ; s e r u z i e S ; c i i t e n k s y d s u m g a t s y N ; .
; i a d e m s i t i t o c i n o r h C ; i a n o t o p y H ; l y a h p e c o r c M i n o i t a p i t s n o C ; ; ) y s p o t u a ( y h p o r t a ) y s p o t u a ( a m e d e l a r b e r e C l a r b e r e C ; y s l a p l a r b e r e C s u m s i b a r t S ; s e r u z i e S ; y t i l i b a s i d l a u t c e l l e t n I ) 7 ( i a n o m u e n P s r a e y 7 Z M H l u G 8 6 4 y G p l .
A N ; s e l c s u m e s r a p S l y a h p e c o r c M i ; ) y s p o t u a ( ) y s p o t u a ( a m y h c n e r a p s e r u z i e S ) 4 ( i a n o m u e n p ; y t i l i b a s i d l a u t c e l l e t n I - o h c n o r B s r a e y 4 Z M H l u G 8 6 4 y G p l .
, i a d e m s i t i t o l c i t s a p o p y H , ; i a d e m s i t i t o , ; i a m e r e t c a B ; l y a e d r o t o M ; ; i a n o t o p y H ; l y a h p e c o r c M i i ) d e ﬁ c e p s n u ( ; y s l a p l a r b e r e c s u m s i b a r t S A N ; s e r u z i e S ; ) 5 ( .
; e s o n d e n r u t p u l a i s s o g o r c a M , t r o h S s u o e n a t n o p S s u m g a t s y n A N ; y t i l i b a s i d l a u t c e l l e t n I ) 1 ( .
D R E G D R E G t a ( y t i c i t s a p S ; ) A O M 7 t i s o t y t i l i b a n I ; l y a e d r o t o M ; l w a r c r o ; s e r u t c a r t n o c i p H t i s o t y t i l i b a n I ; ; s s o l e m u o v l r e t t a m - e t i h W ; ) A O M 7 t a ( s e r u z i e S m u l l e b e r e c l c i t s a p o p y H ; ; y h t a p o r u e n ; s u m s i b a r t S s u m g a t s y N ; e t a a p l h g H i ; m u s o l l a c s u p r o c f o i g n n n h T i ; y t i l i b a s i d ; l y a h p e c o r c M i ; .
p G t n e i t a P ; l y a h p e c o r c M i ; e t a a p l h g H i ; s e c l i r t n e v l a r e t a l f o n o i t a t a l i D ; y t i l i b a s i d ; s s o l e m u o v l r e t t a m - .
; , ; s e r u z i e s i l c n o c - c n o t i r o t o m l a r e h p i r e P ; y h t a p o r u e n ; s u m s i b a r t S s u m g a t s y N .
e g a f o s h t n o m A O M , , d e s s e s s a t o n / e b a c i l l p p a t o n A N , s u o g y z o m o h Z M H , s m o t p m y s l a n i t s e t n o r t s a G i I G .

 , l u G 8 6 4 y G p l .

 .
.

 NATURE COMMUNICATIONS | (2022) 13:705 | https://doi.org/10.1038/s41467-022-28330-8 | www.nature.com/naturecommunications NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-022-28330-8 ARTICLE female infant and the new fetal sample failed to produce any other pathogenic or likely pathogenic genotypes.
Over 180 pathogenic variants in GNE have been described since the genetic basis for GNE-myopathy was ﬁrst established in 200118,19.

The majority of reported pathogenic genotypes in GNE consist of two missense variants, and to date, no patient with a biallelic pLoF genotype (consisting of stop-gained, frameshift, or essential splice variants) has been reported17.

This is in line with observations from mouse studies; where complete knockouts of GNE result in embryonic lethality20.
Although GNE p.Asp378Tyr is a known pathogenic variant, it has never before been reported in the homozygous state, only as part of compound heterozygous genotypes with other variants in GNE17,18.

Interestingly, patients with a compound heterozygous genotype including p.Asp378Tyr, have been described to have more severe and earlier onset of symptoms than other GNE-myopathy patients19,21.
Moreover, experimental studies have shown that p.Asp378Tyr has a more drastic effect on GNE enzymatic activity than most other known pathogenic GNE variants; a 60% reduction of epimerase activity and 50% reduced kinase activity22.

We found that among nine couples where both individuals are heterozygous carriers of p.Asp378Tyr, six women have a medical history of miscarriage (66.7%; Table 3).
This is signiﬁcantly higher than the 26.7% of 74,731 Icelandic women with a history of miscarriage (P = 0.0090, OR = 6.0; logistic regression adjusting for mother’s year of birth).

Furthermore, the observed rate of miscarriage, calculated as the ratio between miscarriages and pregnancies is higher among the GNE p.Asp378Tyr carrier couples (mean ratio is 0.29 for carriers compared to 0.07 in the population, P = 8.3 × 10−7; linear regression adjusting for mother’s year of birth).
for each mother, A homozygous missense variant in GLE1 causes early mis- carriage.

Encouraged by the apparent pathogenicity of the two missense variants, CPSF3 p.Gly468Glu and GNE p.Asp378Tyr, in the homozygous state, we looked into other missense variants showing a complete deﬁcit of homozygous carriers in the popu- lation set (Supplementary Data 1).
Among these variants was c.1706G > A (p.Arg569His) (RefSeq NM_001003722.2) in GLE1 (MAF = 0.82%), with ten homozygous carriers expected in the population set, but none observed (Table 3).

GLE1 p.Arg569His has been described as pathogenic when part of compound het- erozygous genotypes with other variants in GLE1, causing AR lethal congenital contracture syndrome 1 (LCCS1, MIM 253310)8,23,24.
This severe condition, as well as the other GLE1- related disease; congenital arthrogryposis with anterior horn cell disease (CAAHD, MIM 611890), leads to death in the perinatal period in the majority of identiﬁed cases23.

Similar to GNE p.Asp378Tyr, GLE1 p.Arg569His has never been reported in the homozygous state.

In our population set, we identiﬁed 17 couples where both individuals were heterozygous carriers of p.Arg569His.
Despite an evident deﬁcit of homozygous carriers of p.Arg569His, we did not observe premature death or severe disease among the offspring of these 17 carrier couples.

Moreover, we did not detect a signiﬁcant association of p.Arg569His with clinically conﬁrmed miscarriage (N = 19,965 mothers with a history of miscarriage and N = 54,766 controls, P = 0.02; OR = 1.2).
Considering the high deﬁcit of homozygous carriers of GLE1 p.Arg569His, we postulated that homozygosity for the variant would result in lethality in the ﬁrst trimester (before week 13), that would be under-registered in medical records.

We investigated medical records including subsequent childbirth records and interviews, from 11 women out of the 17 couples.

Seven (63.6%) mentioned one or more carrier speciﬁc to early miscarriage, spontaneous abortions at an approximate gestational age of 5–8 weeks.
In comparison, reported rates of miscarriage are 12–24% for all clinically conﬁrmed pregnancies25,26.

The high incidence of early miscarriage among GLE1 p.Arg569His carrier couples, along with the deﬁcit of homozygous carriers, strongly suggests early embryonic death.

that homozygosity for p.Arg569His causes Discussion We describe a set of missense variants with a complete deﬁcit of observed homozygous carriers in a set representative of the adult Icelandic population.
Guided by the homozygote deﬁcit, we dis- covered that missense variants in CPSF3 cause a severe intellec- tual disability syndrome in homozygous carriers.

Prior to this current work, sequence variants in CPSF3 were not reported to cause disease.

We describe six CPSF3 patients in Iceland and the US, who are homozygous for one of two missense variants; p.Gly468Glu and p.Ile354Thr.
Near-complete genealogical information for the Icelandic population set allowed us to discover previous, unrecognized, homozygous carriers of the Icelandic variant, p.Gly468Glu.

Based on the genealogical infor- mation we found three p.Gly468Glu carrier couples who, com- bined, had four children who had died prematurely.

We managed to test archival samples for two of these children, and conﬁrm a homozygous genotype.
CPSF3 encodes Cleavage And Polyadenylation Speciﬁcity Factor 3 (CPSF3 or CPSF73), a 73 kDa subunit of the Cleavage and Polyadenylation Speciﬁcity Factor (CPSF) complex27.

Clea- vage and polyadenylation of the 3′ end of precursor mRNAs (pre- mRNAs) are necessary before transport out of the nucleus.

The CPSF complex plays a crucial role in this 3′ end cleavage, recognizing the AAUAAA cleavage site and interacting with other factors to implement cleavage27.
CPSF3 has endonuclease activity and is predicted to catalyze cleavage just downstream of the AAUAAA site27.

It is also thought to act as both the endonuclease and 5′−3′ exonuclease in histone pre-mRNA processing28.

The CPSF3 protein consists of 684 amino acids, with two metallo-β-lactamase domains and a conserved β-CASP domain, thus belonging to the metallo-β-lactamase family of zinc- dependent hydrolases29 (Fig.

1).
1).

The p.Gly468Glu variant causes substitution of the small and nonpolar amino acid glycine with glutamic acid, a large negatively charged residue, a change that is likely to affect the CPSF3 protein.

The p.Ile354Thr variant occurs within the β-CASP domain of CPSF3, a domain that controls access to the active site of CPSF3, whereas p.Gly468Glu occurs in a linker domain between the highly con- served second metallo-β-lactamase domain of CPSF3 and the C-terminal domain (Fig.

1).
1).

Cpsf3 knockout mice show early embryonic lethality, and Cpsf3 is homologous to the human CPSF3 with 98.5% amino acid identity30.

Yeast studies have shown that mutations of key residues in the CPSF3 yeast homolog (53% amino acid identity), including within the β-CASP domain, are lethal27.

This suggests that a drastic phenotypic effect will be observed not only from a complete loss of the CPSF3 protein, as seen in knockout mice but also from biallelic variants affecting its enzymatic function.
Both p.Gly468Glu and p.Ile354Thr occur at genomic positions highly conserved across mammalian species, with GERP scores of 5.81 and 5.78, respectively (corresponding to the top 96th percentile of all coding variants)31. the structure of CPSF3 is the ﬁrst member of the cleavage and polyadenylation speciﬁcity factor complex to be associated with a severe Mende- lian disorder.
However, heterozygous variants in the gene CPSF1, encoding cleavage and polyadenylation speciﬁcity factor 1, have early-onset recently been linked to autosomal dominant high myopia32.

A 2019 study presented an inhibitor of CPSF3, NATURE COMMUNICATIONS | (2022) 13:705 | https://doi.org/10.1038/s41467-022-28330-8 | www.nature.com/naturecommunications 5 ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-022-28330-8 2 1 k e e w < e g a i r r a c s i m N 2 1 k e e w > e g a i r r a c s i m N ) .
% 0 0 2 ( ) .

% 6 3 6 ( 5 / 1 1 1 / 7 ) .

% 7 6 6 ( 9 / / O b e p o r u E F A M o N o N 8 7 2 3 8 2 3 6 4 6 0 1 / 0 6 / 0 % 3 0 0 .

% 5 0 0 .

d n a l e c I F A M % 0 6 0 .

% 2 8 0 .

r y T 8 7 3 p s A p .

s i H 9 6 5 g r A p .

E N G 1 E L G .

e t a t s s u o g y z o m o h t n a i r a V a e n e G .
s u o g y z o m o h Z M H , d e t c e p x e / d e v r e s b o E / O , y c n e u q e r f e e l l l a i r o n m F A M .

 , s r e d n a l e c I 4 5 0 3 5 1 , .
s r e d n a e c I l d e p y t o n e g - p h c i 4 5 0 3 5 1 , .

 - n o n S G W / S E W 3 0 6 4 6 , n o d e s a B b JTE-607, a small molecule that was developed as an inﬂammatory cytokine inhibitor but had an unknown mode of action until its interaction with CPSF3 was discovered33.
Inhibition of CPSF3, and blocking the release of newly synthesized pre-mRNAs, can enforce cellular apoptosis and has been considered as potential cancer Importantly, however, modulation of mRNA processing in cancer cell lines is vastly different from a genetic loss of mRNA processing.

Nonetheless, these studies of CPSF3 inactivation underline the critical role of the protein in the mRNA processing pathway.

treatment34,35.
treatment34,35.

In isolation, CPSF3 has weak enzymatic activity, and interaction with other factors of the cleavage and polyadenylation machinery is necessary for efﬁcient cleavage29.

We hypothesize that the two missense variants we describe, p.Gly468Glu and p.Ile354Thr, affect the ability of CPSF3 to bind to other factors involved in the pre-mRNA cleavage mechanism.
This effect could disrupt the pre- mRNA cleavage mechanism, resulting in the accumulation of unprocessed pre-mRNA in cells, which would in turn activate a cellular stress response36.
Taken together, the crucial biological function of CPSF3 in humans, the prior evidence from animal models, and the consistency of the phenotype among the six conﬁrmed homozygous patients, all support the role of the two CPSF3 variants, p.Gly468Glu and p.Ile354Thr, in the intellectual disability syndrome observed among homozygous carrier patients.

Ultimately, follow-up functional studies are needed to document the effects of p.Gly468Glu and p.Ile354Thr on CPSF3 function.
In addition to CPSF3, we also discovered that a missense variant in GNE, p.Asp378Tyr, causes an early-onset myopathic disease in homozygous carriers.

The variant has been reported as part of compound heterozygous genotypes in patients with an adult-onset myopathic disorder known as GNE-myopathy.

In contrast, we ﬁnd that in a homozygous state it causes a drastic disease with cardiac complications, resulting in death in the perinatal period.
We also observe an elevated rate of miscarriage among p.Asp378Tyr carrier couples.

GNE encodes glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase, an enzyme that catalyzes sialic acid biosynthesis37.

Animal studies have suggested that a reduction in sialic acid production is tol- erated to a certain threshold, whereas total knockout of GNE and subsequent complete loss of endogenous sialic acid production is embryonic lethal37.
Based on a complete deﬁcit of homozygous carriers of p.Asp378Tyr in the Icelandic population set, an increase in miscarriage among p.Asp378Tyr carrier couples, and conﬁrmation of the variant in homozygosity in two symptomatic cases, we suggest that homozygosity for p.Asp378Tyr causes a reduction in sialic acid production that is below the critical sia- lylation threshold necessary for early human development.
To our knowledge, this is the ﬁrst report of a pathogenic GNE gen- otype resulting in such a severe phenotype.

Finally, we describe how homozygosity for p.Arg569His in GLE1 leads to early embryonic lethality, manifesting as ﬁrst- trimester miscarriage for mothers from carrier couples, that has until now remained unidentiﬁed.

GLE1 p.Arg569His has pre- viously only been observed as part of a compound heterozygous genotype with other variants in GLE1, causing a severe neonatal condition.
GLE1 encodes GLE1 RNA export mediator, a protein required for the transport of polyadenylated mRNA from the nucleus to the cytoplasm38.

Efﬁcient processing and transport of nuclear mRNA is essential for proper eukaryotic gene expression, and has been implicated in several human diseases39.

Two of the genes we describe, GLE1 and CPSF3, encode proteins with a crucial role in the export of nuclear mRNA, underlining the importance of this biological process in early human development.
In conclusion, we used a deﬁcit of observed homozygous carriers versus their expected number in a large population set to identify pathogenic missense genotypes.
We believe our approach may be 6 NATURE COMMUNICATIONS | (2022) 13:705 | https://doi.org/10.1038/s41467-022-28330-8 | www.nature.com/naturecommunications NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-022-28330-8 ARTICLE a CPSF3 3' exon 1 b CPSF3 aa 1 aa 26 Metallo-β-lactamase p.Ile354Thr p.Gly468Glu exon 9 exon 12 5' exon 18 p.Ile354Thr p.Gly468Glu β-CASP aa 246 aa 367 aa 381 Metallo-β- lactamase C-terminal aa 448 aa 479 aa 684 Fig.
1 Structure of CPSF3 (RefSeq transcript NM_016207.3) and location of the two missense variants found in homozygous state in patients with a severe intellectual disability syndrome.

a The p.Ile354Thr and p.Gly468Glu variants are located in exon 9 and 12 of CPSF3, respectively.

Dark gray sections represent exons and untranslated regions, light gray lines represent introns.

b The p.Ile354Thr variant is in the β-CASP domain of CPSF3 (amino acids 246–367, shown in green).
The p.Gly468Glu variant is located within an uncharacterized linker domain (amino acids 448–479) between the critical second metallo-β-lactamase domain (shown in pink) and the highly conserved C-terminal domain (amino acids 479–682, shown in yellow) of CPSF3.

The ﬁrst metallo-β-lactamase domain is shown in blue, uncharacterized domains are shown in gray.
helpful in other large population-based genetic datasets, especially in light of recent data suggesting as high as 1% of unrelated Eur- opean couples are at risk of having offspring with a severe AR genetic disease40.

Until now, the study of genotype-phenotype correlation has mainly been centered on observed genotypes.

We show that the absence of homozygous genotypes from a large population set, given an expected number, can elucidate the causes of previously unexplained AR diseases and early miscarriage.
Methods Population set.

Our approach to WGS, genotyping, long-range phasing, and imputation of a substantial fraction of the Icelandic population has been described in detail in previous publications2,41.

In brief, 56,959 Icelanders participating in various disease projects at deCODE genetics have been WGS using standard TrueSeq methodology (Illumina), to a median depth of 37X, and genotyped with Illumina microarrays (chip-genotyped).

An additional 96,095 Icelanders have been chip-genotyped and not WGS.
Genotypes of sequence variants identiﬁed through sequencing (SNPs and indels) have been imputed into all chip-typed Icelanders, resulting in a set of 153,054 chip-genotyped and imputed Icelanders.

The set consists mainly of adult individuals, 88% were alive at the time of this study, the mean age of living individuals was 58.5 years, and 54% were female.

For the purpose of this study, individuals with either one or both parents of foreign ancestry were removed from the set.
All participating individuals who donated blood or buccal tissue samples, or their guardians, provided written informed consent.

All sample identiﬁers were encrypted in accordance with the regulations of the Icelandic Data Protection Authority.

Personal identities of the participants and biological samples were encrypted by a third-party system approved and monitored by the Icelandic Data Protection Authority.

The study was approved by the Data Protection Authority (ref.
2013030423/ÞS/−, with amendments) and the National Bioethics Committee (ref.

VSN-19-023, VSNb2019010015/03.01), which also reviewed and approved the protocol, methodology, and all documents presented to the participants.

All methods were performed in accordance with the relevant guidelines and regulations.

Clinical set.

For the purpose of clinical WGS we have recruited 764 patients and their family members, amounting to a total of 2501 individuals.
These individuals were recruited in the period 2014–2021, the mean age of the patients was 26.4 years in 2021, and 46% were female.

Samples from patients and family members, sub- mitted to WGS, were from whole-blood, buccal tissue, or puriﬁed DNA.

WGS and genotyping of the set of 2501 were performed as described above.

For the purpose of this study, all individuals recruited on the basis of clinical WGS were removed from the Icelandic population set.

Deﬁning homozygous missense variants of interest.


Based on a given MAF of a sequence variant, a homozygous carrier frequency can be calculated assuming the Hardy-Weinberg equilibrium.

We took variants with a MAF corresponding to an expected homozygous carrier count of three in the population set of 153,054 chip- genotyped and imputed Icelanders.

This corresponded to sequence variants with a MAF over 0.40%.
We considered only genotypes with imputation information over 0.9, excluding variants on the X chromosome.

Analysis of WGS data for clinical purposes.

Sequence variants were called using the Genome Analysis Toolkit (GATK)42, reads were called with GATK using a multi-sample conﬁguration.

Variants were annotated using release 100 of the Variant Effect Predictor (VEP-Ensembl), using RefSeq gene annotations43.
To be able to ﬁlter out genotypes over a certain frequency threshold we used allelic frequencies from phased genotypes of 30 million SNPs and INDELs from 56,959 WGS Icelanders2,41.

Additional frequency ﬁltering was performed using alleles from publicly available datasets of the genome Aggregation Database13.
For the purpose of identifying potentially pathogenic sequence variants we looked at rare (MAF < 2%) coding and splicing variants, including variants with predicted high (stop, frameshift, and splice essential) and moderate (missense, inframe, and splice region) impact on protein function.

We focused on single-nucleotide poly- morphisms (SNPs) and small indels (<20 base pairs).
We prioritized the analysis of the WGS data on variants in phenotypically relevant genes, i.e., genes with a known link to Mendelian disorders (according to Online Mendelian Inheritance in Men) that ﬁt the phenotypes of interest.

All candidate sequence variants were submitted to the ACMG criteria for classiﬁcation as likely benign, benign, variants of uncertain signiﬁcance (VUS), likely pathogenic, or pathogenic44.

Validation by Sanger sequencing.


Samples from all individuals homozygous for p.Gly468Glu in CPSF3 and p.Asp378Tyr in GNE, along with their ﬁrst-degree family members, were Sanger sequenced for conﬁrmation of their respective genotypes.

Primers for Sanger sequencing were designed using the Primer 3 software45.
Following PCR, cycle sequencing reactions were performed in both directions on MJ Research PTC-225 thermal cyclers, using the BigDye Terminator Cycle Sequencing Kit v3.1 (Thermo Fisher Scientiﬁc, Waltham, MA, USA) and Ampure XP and CleanSeq kits (Beckman Coulter, High Wycombe, UK) for cleanup of the PCR products and cycle sequencing reactions.
Sequencing products were run on the 3730 XL DNA Analyzer (Applied Biosystems™, Thermo Fisher Scientiﬁc) and analyzed with the Sequencher 5.4 software (Gene Codes Corpora- tion, Ann Arbor, MI, USA).

Protein analysis.
Protein analysis.

PBMCs were isolated from a venous blood sample from one CPSF3 p.Gly468Glu homozygous carrier (patient B) via standard Ficoll-Paque (GE Health, Uppsala, Sweden, #17144002) density gradient centrifugation at 800 × g for 15 min in 50 ml Blood-Sep spin tubes (DACOS, Denmark, #037100SI) and cryo- preserved in liquid nitrogen.

Thawed cells were transformed using Epstein Barr virus.
For western blot analysis, EBV transformed cells were lysed in RIPA buffer NATURE COMMUNICATIONS | (2022) 13:705 | https://doi.org/10.1038/s41467-022-28330-8 | www.nature.com/naturecommunications 7 ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-022-28330-8 (150 mM sodium chloride, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris pH 8), run on 4–12% gel (Invitrogen, Kiryat Shmona, Israel, #NW04127BOX) and blotted on a PVDF membrane (Novex, #IB24002).
The membrane was blocked, then stained with CPSF3 (Abcam, #ab72295) and beta actin (Abcam, #ab6276) primary antibodies in 5% milk in TBS-T (200 mM Tris, 1500 mM NaCl, 0.1% Tween-20) overnight and mouse (LI-COR, 926–32212) and rabbit (LI- COR, #926–68073) secondary antibodies in TBS-T for 1 h. The membrane was scanned using the Odyssey infrared imaging system (LI-COR Biosciences).

Reporting summary.
Reporting summary.

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability Our previously described Icelandic population whole-genome sequence data3 have been deposited at the European Variation Archive under accession PRJEB15197.

All other data supporting the ﬁndings of this study are available within the article and its supplementary ﬁles.
Code availability We used the following publicly available software for analysis of the WGS data: BWA- MEM version 0.7.10, available at https://github.com/lh3/bwa, GenomeAnalysisTKLite version 2.3.9, available at https://github.com/broadgsa/gatk/, Picard tools version 1.117, available at https://broadinstitute.github.io/picard/, SAMtools version 1.3, available at http://samtools.github.io/, and Variant Effect Predictor (release 100), available at https:// github.com/Ensembl/ensembl-vep.
For association testing we used BOLT-LMM version 2.1, available at https://data.broadinstitute.org/alkesgroup/BOLT-LMM/downloads/.

We used R version 3.6.0 to analyze data and create plots.

Received: 25 August 2021; Accepted: 20 January 2022; References 1.

Allendorf, F. W. Genetic drift and the loss of alleles versus heterozygosity.

Zoo.

Biol.

5, 181–190 (1986).

2.

Gudbjartsson, D. F. et al.

Large-scale whole-genome sequencing of the Icelandic population.

Nat.

Genet.

47, 435–444 (2015).


Jónsson, H. et al.

Whole genome characterization of sequence diversity of 15,220 Icelanders.

Sci.

Data 4, 1–9 (2017).

3.

4.

Arnadottir, G. A. et al.

Compound heterozygous mutations in UBA5 causing early-onset epileptic encephalopathy in two sisters.

BMC Med.

Genet.

18, 103 (2017).

Jensson, B. O. et al.

COPA syndrome in an Icelandic family caused by a recurrent missense mutation in COPA.

BMC Med.

Genet.

18, 129 (2017).

5.

6.

Arnadottir, G. A. et al.


A homozygous loss-of-function mutation leading to CYBC1 deﬁciency causes chronic granulomatous disease.

Nat.

Commun.

9, 1–9 (2018).

7.

Marshall, C. R. et al.

Best practices for the analytical validation of clinical 8.

9. whole-genome sequencing intended for the diagnosis of germline disease.

npj Genomic Med.

5, 1–12 (2020).

Ellard, S. et al.

An exome sequencing strategy to diagnose lethal autosomal recessive disorders.

Eur.

J. Hum.

Genet.


23, 401–404 (2015).

Sulem, P. et al.

Identiﬁcation of a large set of rare complete human knockouts.

Nat.

Genet.

47, 448–452 (2015).

10.

Gerasimavicius, L., Liu, X.

& Marsh, J.

A. Identiﬁcation of pathogenic missense mutations using protein stability predictors.

Sci.

Rep. 10, 1–10 (2020).

11.

Samocha, K. E. et al.

A framework for the interpretation of de novo mutation in human disease.

Nat.

Genet.

46, 944–950 (2014).

12.

Lek, M. et al.


Analysis of protein-coding genetic variation in 60,706 humans.

Nature 536, 285–291 (2016).

13.

Karczewski, K. J. et al.

The mutational constraint spectrum quantiﬁed from variation in 141,456 humans.

Nature 581, 434–443 (2020).

14.

Amendola, L. M. et al.

Performance of ACMG-AMP variant-interpretation guidelines among nine laboratories in the Clinical Sequencing Exploratory Research consortium.

Am.

J. Hum.

Genet.

98, 1067–1076 (2016).

15.


Sobreira, N., Schiettecatte, F., Valle, D. & Hamosh, A. GeneMatcher: a matching tool for connecting investigators with an interest in the same gene.

Hum.

Mutat.

36, 928–930 (2015).

16.

Dawes, R., Lek, M. & Cooper, S. T. Gene discovery informatics toolkit deﬁnes candidate genes for unexplained infertility and prenatal or infantile mortality.

npj Genomic Med.

4, 1–11 (2019).

17.

Celeste, F. V. et al.


Mutation update for GNE gene variants associated with GNE myopathy.

Hum.

Mutat.

35, 915–926 (2014).

18.

Eisenberg, I. et al.

The UDP-N-acetylglucosamine 2-epimerase/N- acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy.

Nat.

Genet.

29, 83–87 (2001).

19.

Pogoryelova, O. et al.

GNE genotype explains 20% of phenotypic variability in GNE myopathy.

Neurol.

Genet.

5, e308 (2019).

20.


Malicdan, M. C. V., Noguchi, S., Nonaka, I., Hayashi, Y. K. & Nishino, I.

A Gne knockout mouse expressing human GNE D176V mutation develops features similar to distal myopathy with rimmed vacuoles or hereditary inclusion body myopathy.

Hum.

Mol.

Genet.

16, 2669–2682 (2007).

21.

Chaouch, A. et al.

Two recurrent mutations are associated with GNE myopathy in the North of Britain.

J. Neurol.

Neurosurg.

Psychiatry 85, 1359–1365 (2014).

22.

Penner, J. et al.


Inﬂuence of UDP-GlcNAc 2-epimerase/ManNAc kinase mutant proteins on hereditary inclusion body myopathy.

Biochemistry 45, 2968–2977 (2006).

23.

Nousiainen, H. O. et al.

Mutations in mRNA export mediator GLE1 result in a fetal motoneuron disease.

Nat.

Genet.

40, 155–157 (2008).

24.

Said, E. et al.

Survival beyond the perinatal period expands the phenotypes caused by mutations in GLE1.

Am.

J. Med.

Genet.

A.

173, 3098–3103 (2017).


Jurkovic, D., Overton, C. & Bender-Atik, R. Diagnosis and management of ﬁrst trimester miscarriage.

BMJ 346, f3676 (2013).

25.

26.

Laisk, T. et al.

The genetic architecture of sporadic and multiple consecutive miscarriage.

Nat.

Commun.

11, 1–12 (2020).

27.

Ryan, K., Calvo, O.

& Manley, J. L. Evidence that polyadenylation factor CPSF-73 is the mRNA 3′ processing endonuclease.

RNA 10, 565–573 (2004).

28.

Dominski, Z., Yang, X.


& Marzluff, W. F. The polyadenylation factor CPSF-73 is involved in histone-pre-mRNA processing.

Cell 123, 37–48 (2005).

29.

Muñoz-Fuentes, V. et al.

The International Mouse Phenotyping Consortium (IMPC): a functional catalogue of the mammalian genome that informs conservation.

Conserv.

Genet.

Print.

19, 995–1005 (2018).

30.


Clerici, M., Faini, M., Aebersold, R. & Jinek, M. Structural insights into the assembly and polyA signal recognition mechanism of the human CPSF complex.

eLife 6, e33111 (2017).

31. Cooper, G. M. et al.

Distribution and intensity of constraint in mammalian genomic sequence.

Genome Res.

15, 901–913 (2005).

32.

Ouyang, J. et al.

CPSF1 mutations are associated with early-onset high myopia and involved in retinal ganglion cell axon projection.

Hum.

Mol.
Hum.

Mol.

Genet.

28, 1959–1970 (2019).

33.

Kakegawa, J., Sakane, N., Suzuki, K. & Yoshida, T. JTE-607, a multiple cytokine production inhibitor, targets CPSF3 and inhibits pre-mRNA processing.

Biochem.

Biophys.

Res.

Commun.

518, 32–37 (2019).

34.

Ross, N. T. et al.

CPSF3-dependent pre-mRNA processing as a druggable node in AML and Ewing’s sarcoma.

Nat.

Chem.

Biol.

16, 50–59 (2020).

35.

Zhu, Z.-H., Yu, Y. P., Shi, Y.-K., Nelson, J.

B.


& Luo, J.-H. CSR1 induces cell death through inactivation of CPSF3.

Oncogene 28, 41–51 (2009).

36.

Teloni, F. et al.

Efﬁcient pre-mRNA cleavage prevents replication-stress- associated genome instability.

Mol.

Cell 73, 670–683.e12 (2019).

37.

Hinderlich, S., Weidemann, W., Yardeni, T., Horstkorte, R. & Huizing, M. UDP-GlcNAc 2-epimerase/ManNAc kinase (GNE), a master regulator of sialic acid synthesis.

Top.

Curr.

Chem.

366, 97–137 (2015).

38.


Rayala, H. J., Kendirgi, F., Barry, D. M., Majerus, P. W. & Wente, S. R. The mRNA export factor human Gle1 interacts with the nuclear pore complex protein Nup155.

Mol.

Cell.

Proteomics 3, 145–155 (2004).

39.

Hurt, J.

A.

& Silver, P. A. mRNA nuclear export and human disease.

Dis.

Model.

Mech.

1, 103–108 (2008).

40.

Fridman, H. et al.

The landscape of autosomal-recessive pathogenic variants in European populations reveals phenotype-speciﬁc effects.
Am.

J. Hum.

Genet.

108, 608–619 (2021).

Jónsson, H. et al.

Parental inﬂuence on human germline de novo mutations in 1,548 trios from Iceland.

Nature 549, 519–522 (2017).

41.

42.

McKenna, A. et al.

The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data.

Genome Res.

20, 1297–1303 (2010).

43.

McLaren, W. et al.

The ensembl variant effect predictor.

Genome Biol.

17, 122 (2016).

44.

Richards, S. et al.


Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Genet.

Med.

17, 405–424 (2015).

45.

Untergasser, A. et al.

Primer3—new capabilities and interfaces.

Nucleic Acids Res.

40, e115 (2012).


Acknowledgements We wish to thank the patients and family members followed in this study, and all other individuals who participated in the study and whose contribution made this work pos- sible.

M.T.S.

was supported by a grant from the Sacchi Foundation.
8 NATURE COMMUNICATIONS | (2022) 13:705 | https://doi.org/10.1038/s41467-022-28330-8 | www.nature.com/naturecommunications NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-022-28330-8 ARTICLE Author contributions G.A.A., A.O., H.T.B., U.T., P.S.

and K.S.

designed the study.

G.A.A., B.O.J., H.K., R.F.

and P.S.

carried out or supervised analysis of clinical WGS data.

S.G. carried out analysis of medical records.

S.G., M.T.S., R.B., P.L., J.J.J., O.Th., Jo.A.

and H.T.B.
and H.T.B.

met with patients and families involved in the study.

A.O.A.

and G.L.N.

carried out or supervised laboratory experiments.

J.S., L.R., Ju.A.,Th.S., I.J., H.H.

and J.G.J.

carried out or super- vised the collection of biological samples.

G.M.

and D.F.G.

developed the methods for data analysis.

O.Th.M., Ad.J.

and As.J.

carried out sequencing.

G.A.A., A.O., E.V.I., G.R.O., K.R.G., D.F.G.

and P.S.

performed statistical and bioinformatics analyses.


G.A.A., A.O., B.O.J., D.F.G., H.T.B., U.T., P.S.

and K.S.

drafted the manuscript.

All authors contributed to the ﬁnal version of the paper.

Competing interests Authors afﬁliated with deCODE genetics/Amgen declare competing interests as employees.

The remaining authors declare no competing interests.
Additional information Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41467-022-28330-8.

Peer review information Nature Communications thanks Victoria Jackson and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Peer reviewer reports are available.


Reprints and permission information is available at http://www.nature.com/reprints Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional afﬁliations.
Open Access This article is licensed under a Creative Commons Attri- bution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.

If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Correspondence and requests for materials should be addressed to Patrick Sulem or Kari Stefansson.

© The Author(s) 2022 NATURE COMMUNICATIONS | (2022) 13:705 | https://doi.org/10.1038/s41467-022-28330-8 | www.nature.com/naturecommunications 9